The Effects of Autologous Platelet-rich Plasma Supplement During Sperm Cryopreservation on Post-cryopreserved Sperm Quality

Last updated: February 5, 2024
Sponsor: Rajavithi Hospital
Overall Status: Active - Recruiting

Phase

N/A

Condition

In Vitro Fertilization

Treatment

no autologous platelet-rich plasma supplement

autologous platelet-rich plasma supplement

Clinical Study ID

NCT06258759
151/2566
  • Ages 20-40
  • Male
  • Accepts Healthy Volunteers

Study Summary

Sperm cryopreservation is an essential procedure for male fertility in certain situations, like cancer, vasectomy or other obstructive surgeries, autoimmunity diseases, immunosuppressive therapeutic strategies, or when the male partner is incapable of providing sufficient spermatozoa on the day of egg retrieval. Semen cryopreservation is mainly associated with decreased viability, motility, and DNA damage of spermatozoa due to the osmotic and mechanical stresses attributed to the freezing-thaw- ing process. Sperm cryodamage mainly originates from osmotic changes, cold shock, intracellular ice crystal formation, and oxidative stress. Based on this, some protective strategies have been proposed and developed, even the addition of cryoprotectants. Recently, Platelet-rich plasma (PRP) is becoming very popular in medicine. The therapeutic effect of platelets is related to alpha granule contents. A study showed that PRP modulates ROS toxicity through a different mechanism. VEGF detoxify oxidative damage via activation of the nuclear factor (erythroid- derived 2)-like2 (Nrf2) pathway. Oxidative stress modulation and apoptosis inhibition both have an essential role during the cryopreservation process. In this case, it raises the question of whether PRP can improve the sperm quality against freeze-thawing-induced damage. Therefore, the present study aimed to examine different concentrations of PRP on frozen-thawed sperm parameters of vitality, morphology, motility and DNA fragmentation

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. A man who be a Rajavithi hospital clients or staff.
  2. Aged 20-40 years old.
  3. Has normal semen analysis.
  4. Can communicate and understand Thai language very well.
  5. Voluntarily participated in the research.
  6. Sexual abstinence for 2-7 days.

Exclusion

Exclusion Criteria:

  1. A man who ever diagnosed with infertile patient.
  2. A wan who diagnosed with any hematological disease such as Coagulation disorders,Hypertension, Thrombocytopenia, Platelet dysfunction.

Study Design

Total Participants: 20
Treatment Group(s): 2
Primary Treatment: no autologous platelet-rich plasma supplement
Phase:
Study Start date:
January 01, 2024
Estimated Completion Date:
December 31, 2024

Study Description

  • Each participant will be collected a semen and PRP.

  • Each semen will be separated into two specimens as the additional autologous platelet-rich plasma supplement group and control group (no adding autologous platelet-rich plasma). Both groups will undergo cryopreservation by Sperm vitrification for 14 days.

  • The additional autologous platelet-rich plasma supplement group: the semen will be added by 5% PRP and mixed with Sperm Freezing Medium and undergo cryopreservation by Sperm vitrification for 14 days.

  • The control group (no adding autologous platelet-rich plasma): the semen will be mixed with Sperm Freezing Medium and undergo cryopreservation by Sperm vitrification for 14 days.

  • After 14 days, the vitrified semen was transferred to a water bath of 37 °C for thawing. And analyzed Semen analysis via Computer Assisted Sperm Analysis: CASA and analyzed DNA fragmentation

Connect with a study center

  • Rajavithi hospital

    Bangkok, 10400
    Thailand

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.